• Incidence of grade 3 or 4 allergic reactions [ Time Frame: Within 30 days of last treatment administration ] [ Designated as safety issue: Yes ]
  

ecause they were excluded from most of the clinical trials of non-recombinant urate oxidase and rasburicase, the safety of rasburicase in this population is not known, though preliminary data indicates that the drug is safe. The primary objective of this study is to estimate the proportion of grade 3 or 4 allergic reactions to rasburicase in patients with a history of asthma or severe allergy (to antigens other than rasburicase or other urate oxidases) treated with rasburicase for the prevention or treatment of malignancy or chemotherapy-induced hyperuricemia. Patients at risk of tumor lysis syndrome with a history of asthma/atopy will be treated with rasburicase according to standard practice and observed for allergic reactions.

Inclusion Criteria:

• Patient is less than or equal to 21 years of age
• Patient has a diagnosis of hematologic malignancy
• Patient has hyperuricemia or is at high risk of developing hyperuricemia of malignancy
• Patient has a history of asthma or significant allergy
• No prior exposure to rasburicase or other urate oxidase

Exclusion Criteria

• Pregnancy or lactation
• Wheezing or an active hypersensitivity reaction at entry
• Hypersensitivity to Aspergillus proteins
• Significant airway compression
• Known history of G6PD deficiency